摘要
Background: Although eradication of Helicobacter pylori infection can decrease the risk of gastric cancer, the optimal regimen for treating the general population remains unclear. We report the eradication rate (intention-to-treat and per protocol) of a community-based H. pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Materials and methods: In 2004, a total of 2658 residents were recruited for 13C-urea breath testing. Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily), and a 10-day re-treatment (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) if the follow-up tests remained positive. Both H. pylori status and side-effects were assessed 6 weeks after treatment. Results: Among 886 valid reporters, eradication rates with initial therapy were 86.9% (95% confidence interval [CI]: 84.7-89.1%) and 88.7% (95%CI: 86.5-90.9%) by intention-to-treat and per protocol analysis, respectively. Re-treatment eradicated infection in 91.4% (95%CI: 86-96.8%) of 105 nonresponders. Adequate compliance was achieved in 798 (90.1%) of 886 subjects receiving the initial treatment and in all 105 re-treated subjects. Mild side-effects occurred in 24% of subjects. Overall intention-to-treat and per protocol eradication rates were 97.7% (95%CI: 96.7-98.7%) and 98.8% (95%CI: 98.5-99.3%), respectively, which were only affected by poor compliance (odds ratio, 3.3; 95%CI, 1.99-5.48; p
原文 | 英語 |
---|---|
頁(從 - 到) | 418-424 |
頁數 | 7 |
期刊 | Helicobacter |
卷 | 11 |
發行號 | 5 |
DOIs | |
出版狀態 | 已發佈 - 十月 2006 |
指紋
ASJC Scopus subject areas
- Gastroenterology
- Microbiology
引用此文
A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. / Lee, Yi Chia; Wu, Hui Min; Chen, Tony Hsiu Hsi; Liu, Tzeng Ying; Chiu, Han Mo; Chang, Chun Chao; Wang, Hsiu Po; Wu, Ming Shiang; Chiang, Hung; Wu, Meng Chen; Lin, Jaw Town.
於: Helicobacter, 卷 11, 編號 5, 10.2006, p. 418-424.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures
AU - Lee, Yi Chia
AU - Wu, Hui Min
AU - Chen, Tony Hsiu Hsi
AU - Liu, Tzeng Ying
AU - Chiu, Han Mo
AU - Chang, Chun Chao
AU - Wang, Hsiu Po
AU - Wu, Ming Shiang
AU - Chiang, Hung
AU - Wu, Meng Chen
AU - Lin, Jaw Town
PY - 2006/10
Y1 - 2006/10
N2 - Background: Although eradication of Helicobacter pylori infection can decrease the risk of gastric cancer, the optimal regimen for treating the general population remains unclear. We report the eradication rate (intention-to-treat and per protocol) of a community-based H. pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Materials and methods: In 2004, a total of 2658 residents were recruited for 13C-urea breath testing. Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily), and a 10-day re-treatment (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) if the follow-up tests remained positive. Both H. pylori status and side-effects were assessed 6 weeks after treatment. Results: Among 886 valid reporters, eradication rates with initial therapy were 86.9% (95% confidence interval [CI]: 84.7-89.1%) and 88.7% (95%CI: 86.5-90.9%) by intention-to-treat and per protocol analysis, respectively. Re-treatment eradicated infection in 91.4% (95%CI: 86-96.8%) of 105 nonresponders. Adequate compliance was achieved in 798 (90.1%) of 886 subjects receiving the initial treatment and in all 105 re-treated subjects. Mild side-effects occurred in 24% of subjects. Overall intention-to-treat and per protocol eradication rates were 97.7% (95%CI: 96.7-98.7%) and 98.8% (95%CI: 98.5-99.3%), respectively, which were only affected by poor compliance (odds ratio, 3.3; 95%CI, 1.99-5.48; p
AB - Background: Although eradication of Helicobacter pylori infection can decrease the risk of gastric cancer, the optimal regimen for treating the general population remains unclear. We report the eradication rate (intention-to-treat and per protocol) of a community-based H. pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Materials and methods: In 2004, a total of 2658 residents were recruited for 13C-urea breath testing. Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily), and a 10-day re-treatment (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) if the follow-up tests remained positive. Both H. pylori status and side-effects were assessed 6 weeks after treatment. Results: Among 886 valid reporters, eradication rates with initial therapy were 86.9% (95% confidence interval [CI]: 84.7-89.1%) and 88.7% (95%CI: 86.5-90.9%) by intention-to-treat and per protocol analysis, respectively. Re-treatment eradicated infection in 91.4% (95%CI: 86-96.8%) of 105 nonresponders. Adequate compliance was achieved in 798 (90.1%) of 886 subjects receiving the initial treatment and in all 105 re-treated subjects. Mild side-effects occurred in 24% of subjects. Overall intention-to-treat and per protocol eradication rates were 97.7% (95%CI: 96.7-98.7%) and 98.8% (95%CI: 98.5-99.3%), respectively, which were only affected by poor compliance (odds ratio, 3.3; 95%CI, 1.99-5.48; p
KW - Antibiotic regimen
KW - Gastric cancer
KW - Helicobacter pylori
KW - Population-based study
UR - http://www.scopus.com/inward/record.url?scp=33748461592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748461592&partnerID=8YFLogxK
U2 - 10.1111/j.1523-5378.2006.00432.x
DO - 10.1111/j.1523-5378.2006.00432.x
M3 - Article
C2 - 16961802
AN - SCOPUS:33748461592
VL - 11
SP - 418
EP - 424
JO - Helicobacter
JF - Helicobacter
SN - 1083-4389
IS - 5
ER -